Form 4: T2 Biosystems Chief Commercial Officer Awarded 360,000 Restricted Stock Units

T2 Biosystems' Chief Commercial Officer, Brett A. Giffin, was granted 360,000 restricted stock units (RSUs) on November 4, 2024, which vest over time.

Summary

• Brett A. Giffin, the Chief Commercial Officer of T2 Biosystems, was granted a total of 360,000 restricted stock units (RSUs) on November 4, 2024.
• 180,000 of these RSUs will vest in one installment on May 4, 2025.
• The other 180,000 RSUs will vest in three equal annual installments starting on November 4, 2025.
• Both grants were contingent on stockholder approval of the amendment and restatement of the company's 2014 Incentive Award Plan.
• The stockholder approval was obtained on December 30, 2024.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, which is generally positive for aligning management interests with shareholders. The sentiment is neutral to slightly positive.

Positives

• The grant of RSUs to the Chief Commercial Officer aligns his interests with the long-term success of the company.
• The vesting schedule encourages continued service and performance from the executive.

Risks

• The value of the RSUs is dependent on the future performance of T2 Biosystems' stock price.
• There is a risk that the executive may leave the company before the RSUs fully vest.

Future Outlook

The vesting of the RSUs is contingent on the executive's continued employment with the company and the future performance of the stock.

Industry Context

The granting of stock-based compensation is a common practice in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Stock-based compensation is a standard practice for companies in the biotechnology sector, such as Exact Sciences (EXAS) and Bio-Rad Laboratories (BIO), to incentivize executives.
• The vesting schedule of the RSUs is typical, with some vesting immediately and others vesting over a period of years to encourage long-term commitment.
• The size of the grant is not directly comparable without knowing the specific compensation packages of other executives in similar roles at comparable companies.

Stakeholder Impact

• The RSU grant may have a positive impact on shareholder value if it motivates the executive to improve company performance.
• The grant does not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Restricted Stock Units, RSU, Stock Options, Incentive Award Plan, Executive Compensation, T2 Biosystems, TTOO, Brett A. Giffin